Peyronie'S Disease Clinical Trials 2023

What Are Peyronie's Disease Clinical Trials?

Peyronie's disease is a connective tissue disorder caused by fibrous plaque/scar tissue developed in the soft tissue of the penis. This disease results in a painful and curved erection and typically causes the penis to lose strength and girth.

Clinical trials researching Peyronie's disease consist of a specified number of participants that need to meet the requirements in their applications to qualify for the study. These clinical trials administer and observe the effects of various pharmaceuticals and procedures on patients that suffer from Peyronie's disease. They aim to establish effective treatment plans to manage or cure this disease.

Why Is Peyronie's Disease Being Studied In Clinical Trials?

Clinical trials for Peyronie's disease can help treat, stabilize, and cure the adverse effects and symptoms in patients with this disease. According to the Peyronies Association, Peyronie's disease affects over 9% of men, mainly between the ages of 20 and 70.

What Are The Types of Treatments Available For Peyronie's Disease?

Clinical trials for Peyronie's disease include various methods of treatment that can help medical professionals better understand this disease. These clinical trials consist of multiple treatments, including:

Collagenase Clostridium Histolyticum is administered to patients to treat Peyronie's disease. These patients will then be evaluated and monitored to determine their reaction to these drugs. Furthermore, some clinical trials combine this treatment with penile traction therapy to increase effectiveness.

Penile surgery and penile traction therapy can be very effective as they approach treating patients suffering from Peyronie's disease aggressively. Although surgical clinical trials require extended hospitalization and post-operation treatment periods, they appear to be an effective means of treatment.

Fractional Carbon Dioxide Laser Therapy can treat patients with Peyronie's disease. This therapy can safely and successfully reduce and destroy the scar tissue on the soft tissue of the penis. As a result, it can significantly decrease the negative impact and symptoms of this disease in patients. However, participants must complete several therapy sessions to ensure safe and thorough treatment.

What Are Some Recent Breakthrough Clinical Trials For Peyronie's Disease?

Over the last several years, there have been multiple breakthroughs in treating and diagnosing Peyronie's disease. These breakthroughs have allowed medical professionals to understand and treat this disease better, and they include:

2001: The Acetyl-L-carnitine vs. tamoxifen clinical trial helped medical researchers determine that acetyl-L-carnitine is a safer and more efficient treatment for patients with early stages of chronic Peyronie's disease than tamoxifen.

2015: The Peyronie's Disease: AUA Guideline established the clinical framework that medical professionals use to review and determine the most effective approach for diagnosing and treating individual patients suffering from Peyronie's disease.

2020: The Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase clostridium Histolyticum for Peyronie's Disease clinical trial has concluded that most patients treated with collagenase clostridium histolyticum have continued to show signs of recovery. Further, they did not display any adverse side effects from this treatment.